Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOVENOX (PRESERVATIVE FREE) vs LOVENOX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Low molecular weight heparin (LMWH) that potentiates antithrombin III, accelerating inactivation of factor Xa and thrombin.
Low molecular weight heparin (LMWH) that binds to antithrombin III, enhancing its inhibition of factor Xa and thrombin, thereby preventing thrombus formation.
Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement, knee replacement, or medical patients at risk,Treatment of DVT with or without pulmonary embolism,Prophylaxis of ischemic complications in unstable angina or non-Q-wave myocardial infarction,Treatment of acute ST-segment elevation myocardial infarction (STEMI) managed medically or with percutaneous coronary intervention
Treatment of deep vein thrombosis (DVT),Prevention of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with restricted mobility,Treatment of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) when administered with aspirin,Extended treatment of DVT in cancer patients (off-label)
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily.
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis in abdominal surgery, hip or knee replacement; 30 mg subcutaneously every 12 hours for prophylaxis in medical patients; 0.5 mg/kg subcutaneously once daily for prophylaxis in patients with acute coronary syndrome.
Terminal half-life: 3-5 hours after subcutaneous injection; prolonged in renal impairment (up to 8-10 hours with Cr Cl <30 m L/min).
Terminal half-life: 4.5-7 hours after subcutaneous administration; prolonged in renal impairment (up to 16 hours with Cr Cl <30 m L/min), requiring dose adjustment.
Metabolized primarily by desulfation and depolymerization in the liver via heparinases; renally eliminated as unchanged drug and metabolites.
Primarily metabolized in the liver by desulfation and depolymerization to lower molecular weight fragments with reduced anticoagulant activity.
Renal: 40-60% as unchanged drug and low molecular weight fragments via glomerular filtration; biliary/fecal: negligible.
Renal: 40-60% as active and inactive fragments via glomerular filtration and tubular secretion; biliary/fecal: minimal, <10%.
Approximately 90% bound to antithrombin III (minor binding to other plasma proteins).
Antithrombin III (ATIII) binding: ~100% (enoxaparin is an ATIII-dependent inhibitor); nonspecific protein binding: negligible (<1%).
4-7 L (0.06-0.1 L/kg) – predominantly confined to intravascular space.
Vd: 0.1-0.2 L/kg; confined mainly to intravascular space, with limited extravascular distribution; reflects low tissue penetration.
Subcutaneous: ~90-100% (almost complete absorption).
Subcutaneous: 92-100% (nearly complete).
For Cr Cl <30 m L/min: reduce dose to 1 mg/kg subcutaneously once daily. For Cr Cl 30-50 m L/min: no dose adjustment required, but monitor carefully.
For Cr Cl <30 m L/min: treatment dose 1 mg/kg subcutaneously once daily; prophylaxis dose 30 mg subcutaneously once daily. No adjustment for Cr Cl 30-50 m L/min but monitor closely.
No specific dose adjustment recommended for hepatic impairment; caution in severe hepatic impairment due to increased bleeding risk.
No specific dosing adjustment recommended for hepatic impairment based on Child-Pugh score; use with caution in severe hepatic impairment due to increased risk of bleeding.
Neonates: 1.5 mg/kg subcutaneously every 12 hours. Infants and children: 1 mg/kg subcutaneously every 12 hours.
Prophylaxis: 0.5 mg/kg subcutaneously every 12 hours. Treatment: 1 mg/kg subcutaneously every 12 hours. Maximum single dose 120 mg. Weight must be >5 kg.
No specific dose adjustment, but increased risk of bleeding; monitor renal function and adjust dose if Cr Cl <30 m L/min.
Elderly patients >75 years old: increased risk of bleeding; consider lower doses (e.g., 0.75 mg/kg every 12 hours for treatment) and monitor renal function closely; no specific dose adjustment solely by age but use with caution.
Spinal/epidural hematomas, including subsequent paralysis, may occur in patients anticoagulated with LMWH or heparinoids who receive neuraxial anesthesia or undergo spinal puncture. Risk increased by use of indwelling epidural catheters, concomitant use of drugs affecting hemostasis, history of traumatic or repeated epidural/spinal punctures, or history of spinal deformity or surgery.
Spinal/epidural hematomas may occur in patients anticoagulated with LMWH or heparinoids who receive neuraxial anesthesia or undergo spinal puncture. These hematomas can result in long-term or permanent paralysis.
Risk of bleeding; thrombocytopenia, including heparin-induced thrombocytopenia (HIT); use in renal impairment (reduce dose if Cr Cl <30 m L/min); elderly patients (increased bleeding risk); pregnancy (category B); use with caution in patients with history of heparin-induced thrombocytopenia; monitor for signs of bleeding.
Risk of bleeding, especially with invasive procedures or concomitant use of antiplatelet agents,Heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia with thrombosis (HITTS),Increased risk of spinal/epidural hematoma with neuraxial anesthesia,Use with caution in patients with renal impairment (creatinine clearance <30 m L/min) due to reduced clearance,Monitor for signs of bleeding and thrombocytopenia
Active major bleeding; history of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia with thrombosis (HITT); hypersensitivity to heparin or pork products; not recommended for use in patients with prosthetic heart valves, especially pregnant women (risk of valve thrombosis).
Active major bleeding,History of heparin-induced thrombocytopenia (HIT),Hypersensitivity to enoxaparin, heparin, or pork products,Use of indwelling epidural catheter for analgesia or therapy
No known direct food interactions. However, foods high in vitamin K (e.g., green leafy vegetables, broccoli, Brussels sprouts) may theoretically affect coagulation but are not a concern with LMWH. Avoid or limit alcohol consumption due to increased bleeding risk.
No specific food restrictions; avoid excessive alcohol consumption as it may increase bleeding risk.
Low risk of teratogenicity; enoxaparin does not cross the placenta and is not associated with fetal malformations. In the first trimester, risk of teratogenicity is minimal but consider anticoagulation alternatives if VTE prophylaxis needed; second and third trimesters: no known teratogenic risk, but increased risk of maternal bleeding and placental abruption; perinatal: risk of neonatal bleeding if administered near delivery.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: No known increased risk of major malformations. Second/Third trimesters: Risk of maternal hemorrhage, placental abruption, and fetal hemorrhage due to anticoagulant effect. Use only if clearly needed.
Excreted into breast milk in negligible amounts; M/P ratio not clinically significant; compatible with breastfeeding; no adverse effects in nursing infants reported.
Excreted in human milk in negligible amounts; M/P ratio not established. Considered compatible with breastfeeding; monitor infant for signs of bruising or bleeding.
Dose adjustment not typically required based on pregnancy alone; however, increased plasma volume and renal clearance may necessitate dose escalation; monitor anti-Xa levels and adjust dose to maintain target range (e.g., 0.5-1.0 IU/m L for twice-daily prophylaxis); avoid dose adjustment for physiological anemia.
Renal blood flow increases during pregnancy, potentially increasing clearance. Dose adjustments may be needed in the third trimester based on anti-Xa monitoring. Standard prophylactic dose: 40 mg SC once daily; therapeutic dose: 1 mg/kg SC q12h. Consider weight-based dosing and monitor anti-Xa levels (target 0.5-1.0 IU/m L for therapeutic, 0.2-0.5 IU/m L for prophylaxis).
Lovenox (enoxaparin) is a low molecular weight heparin (LMWH) that does not require routine monitoring of anti-Xa levels except in special populations (e.g., renal impairment, obesity, pregnancy). Use with caution in patients with severe renal impairment (Cr Cl <30 m L/min) as enoxaparin accumulates; consider dose reduction or alternative agent. Protamine sulfate can partially reverse anticoagulation (1 mg protamine per 1 mg enoxaparin). Risk of spinal/epidural hematoma with neuraxial anesthesia or spinal puncture; remove catheter at least 12 hours after last prophylactic dose and 24 hours after last treatment dose. Contraindicated in active major bleeding, history of heparin-induced thrombocytopenia (HIT), or hypersensitivity to heparin products. Calculate dose based on actual body weight, not ideal body weight, for treatment indications.
Enoxaparin is a low molecular weight heparin (LMWH) with predictable pharmacokinetics, eliminating the need for routine monitoring of anti-Xa activity in most patients. Dosing is based on weight and renal function; adjust for Cr Cl <30 m L/min (e.g., 30 mg once daily for VTE prophylaxis). Protamine sulfate partially reverses anticoagulant effect (60% neutralization). Avoid in patients with history of heparin-induced thrombocytopenia (HIT); check platelet counts every 2-3 days during therapy. Subcutaneous injection technique: administer in lateral abdominal wall, pinch skin, insert needle at 45-90° angle, do not rub site. Spinal/epidural hematoma risk with neuraxial anesthesia — remove indwelling catheter at least 12 hours after last prophylactic dose (24 hours for treatment doses).
Do not stop taking or change the dose without consulting your healthcare provider.,Report any signs of bleeding (unusual bruising, prolonged bleeding, blood in urine/stool, coughing up blood, bleeding gums) or injection site reactions (pain, redness, swelling).,Avoid aspirin, NSAIDs (ibuprofen, naproxen), or other blood thinners unless prescribed by your doctor.,Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.,If you have an epidural or spinal tap, inform your doctor that you are taking enoxaparin.,Store at room temperature; do not freeze. Use prefilled syringes only once and dispose of properly.,If you miss a dose, take it as soon as possible unless it is almost time for the next dose; do not double the dose.
Inject enoxaparin exactly as prescribed; do not skip doses.,Rotate injection sites (left/right side of abdomen) to reduce bruising.,Do not massage the injection site after administration.,Watch for signs of bleeding: unusual bruising, black/tarry stools, pink/red urine, coughing up blood, or severe headache.,Seek emergency care for sudden back pain, numbness, or leg weakness (possible spinal hematoma).,Tell all healthcare providers you are taking this blood thinner before procedures or surgeries.,Use soft toothbrush and electric razor to minimize bleeding risk.,Avoid aspirin, NSAIDs, and other blood thinners unless prescribed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOVENOX (PRESERVATIVE FREE) vs LOVENOX, answered by our medical review team.
LOVENOX (PRESERVATIVE FREE) is a Low Molecular Weight Heparin that works by Low molecular weight heparin (LMWH) that potentiates antithrombin III, accelerating inactivation of factor Xa and thrombin.. LOVENOX is a Low Molecular Weight Heparin that works by Low molecular weight heparin (LMWH) that binds to antithrombin III, enhancing its inhibition of factor Xa and thrombin, thereby preventing thrombus formation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOVENOX (PRESERVATIVE FREE) and LOVENOX depend on the specific clinical indication. These are both Low Molecular Weight Heparin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOVENOX (PRESERVATIVE FREE) is: 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily.. The standard adult dose of LOVENOX is: 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis in abdominal surgery, hip or knee replacement; 30 mg subcutaneously every 12 hours for prophylaxis in medical patients; 0.5 mg/kg subcutaneously once daily for prophylaxis in patients with acute coronary syndrome.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOVENOX (PRESERVATIVE FREE) and LOVENOX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOVENOX (PRESERVATIVE FREE) is classified as Category C. Low risk of teratogenicity; enoxaparin does not cross the placenta and is not associated with fetal malformations. In the first trimester, risk of teratogenicity is minimal but con. LOVENOX is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: No known increased risk of major malformations. Second/Third trimesters: Risk of materna. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.